25 XP 0   0   10  
0coffee
Main menu
3rd party ad coffee SUPPORTERis ad-free.

Arrowhead Pharmaceuticals Inc
Buy, Hold or Sell?

Let's analyze Arrowhead Pharmaceuticals Inc together

I guess you are interested in Arrowhead Pharmaceuticals Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Arrowhead Pharmaceuticals Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

Get notifications about Arrowhead Pharmaceuticals Inc

I send you an email if I find something interesting about Arrowhead Pharmaceuticals Inc.

1. Quick Overview

1.1. Quick analysis of Arrowhead Pharmaceuticals Inc (30 sec.)










1.2. What can you expect buying and holding a share of Arrowhead Pharmaceuticals Inc? (30 sec.)

How much money do you get?

How much money do you get?
$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
$1.53
Expected worth in 1 year
$0.76
How sure are you?
32.5%

+ What do you gain per year?

Total Gains per Share
$-0.77
Return On Investment
-3.3%

For what price can you sell your share?

Current Price per Share
$23.27
Expected price per share
$18.03 - $29.93
How sure are you?
50%
3rd party ad coffee SUPPORTERis ad-free.

2. Detailed Analysis

2.1. Valuation of Arrowhead Pharmaceuticals Inc (5 min.)




Live pricePrice per Share (EOD)
$23.27
Intrinsic Value Per Share
$-70.98 - $-28.20
Total Value Per Share
$-69.44 - $-26.66

2.2. Growth of Arrowhead Pharmaceuticals Inc (5 min.)




Is Arrowhead Pharmaceuticals Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$191m$382.6m-$82.8m-27.6%

How much money is Arrowhead Pharmaceuticals Inc making?

Current yearPrevious yearGrowGrow %
Making money-$149.8m-$51.4m-$98.4m-65.7%
Net Profit Margin-935.4%-341.4%--

How much money comes from the company's main activities?

2.3. Financial Health of Arrowhead Pharmaceuticals Inc (5 min.)




2.4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#261 / 945

Most Revenue
#507 / 945

Most Profit
#921 / 945

Most Efficient
#689 / 945
3rd party ad coffee SUPPORTERis ad-free.

3. Summary and Key Metrics

3.1. What can you expect buying and holding a share of Arrowhead Pharmaceuticals Inc?

Welcome investor! Arrowhead Pharmaceuticals Inc's management wants to use your money to grow the business. In return you get a share of Arrowhead Pharmaceuticals Inc.

First you should know what it really means to hold a share of Arrowhead Pharmaceuticals Inc. And how you can make/lose money.

Speculation

The Price per Share of Arrowhead Pharmaceuticals Inc is $23.27. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Arrowhead Pharmaceuticals Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Arrowhead Pharmaceuticals Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is $1.53. Based on the TTM, the Book Value Change Per Share is $-0.19 per quarter. Based on the YOY, the Book Value Change Per Share is $0.36 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is $0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Arrowhead Pharmaceuticals Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 $% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share$% of Price per Share
Usd Eps-1.37-5.9%-1.20-5.2%-0.41-1.8%-0.48-2.1%-0.28-1.2%
Usd Book Value Change Per Share-1.19-5.1%-0.19-0.8%0.361.6%-0.02-0.1%0.010.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-1.19-5.1%-0.19-0.8%0.361.6%-0.02-0.1%0.010.0%
Usd Price Per Share19.37-26.14-32.12-44.02-26.74-
Price to Earnings Ratio-3.53--5.63--8.17--65.09--33.66-
Price-to-Total Gains Ratio-16.29--14.87--6.32--499.34--274.51-
Price to Book Ratio12.62-12.82-10.70-15.23-12.15-
Price-to-Total Gains Ratio-16.29--14.87--6.32--499.34--274.51-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share23.27
Number of shares42
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.19-0.02
Usd Total Gains Per Share-0.19-0.02
Gains per Quarter (42 shares)-8.11-0.90
Gains per Year (42 shares)-32.46-3.58
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-32-420-4-14
20-65-740-7-18
30-97-1060-11-22
40-130-1380-14-26
50-162-1700-18-30
60-195-2020-21-34
70-227-2340-25-38
80-260-2660-29-42
90-292-2980-32-46
100-325-3300-36-50

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.04.00.00.0%2.010.00.016.7%2.018.00.010.0%6.034.00.015.0%14.092.01.013.1%
Book Value Change Per Share1.03.00.025.0%5.07.00.041.7%6.014.00.030.0%13.027.00.032.5%36.066.05.033.6%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%0.00.040.00.0%0.00.0107.00.0%
Total Gains per Share1.03.00.025.0%5.07.00.041.7%6.014.00.030.0%13.027.00.032.5%36.066.05.033.6%
3rd party ad coffee SUPPORTERis ad-free.

3.2. Key Performance Indicators

The key performance indicators of Arrowhead Pharmaceuticals Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---1.189-0.193-84%0.364-427%-0.021-98%0.005-23768%
Book Value Per Share--1.5352.409-36%3.075-50%3.145-51%2.062-26%
Current Ratio--6.7415.860+15%6.210+9%5.600+20%5.543+22%
Debt To Asset Ratio--0.8320.663+26%0.545+53%0.433+92%0.330+152%
Debt To Equity Ratio--5.1162.634+94%1.291+296%1.295+295%0.809+533%
Dividend Per Share----0%-0%-0%-0%
Enterprise Value--2143376356.0003116717704.000-31%4003277415.000-46%5555647701.350-61%3401474597.350-37%
Eps---1.370-1.204-12%-0.412-70%-0.483-65%-0.281-80%
Ev To Ebitda Ratio---3.499-5.762+65%-8.861+153%-57.393+1540%-30.293+766%
Ev To Sales Ratio--infinfnan%36.790+inf%infnan%infnan%
Free Cash Flow Per Share---1.297-1.214-6%-0.664-49%-0.435-66%-0.229-82%
Free Cash Flow To Equity Per Share--1.8280.535+242%-0.156+109%0.150+1115%0.103+1676%
Gross Profit Margin--1.0001.0020%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---28.196--------
Intrinsic Value_10Y_min---70.978--------
Intrinsic Value_1Y_max---1.193--------
Intrinsic Value_1Y_min---3.731--------
Intrinsic Value_3Y_max---4.830--------
Intrinsic Value_3Y_min---14.205--------
Intrinsic Value_5Y_max---9.965--------
Intrinsic Value_5Y_min---27.882--------
Market Cap2895579180.000+17%2411154356.0003252921704.000-26%3997131165.000-40%5477254766.800-56%3327060215.150-28%
Net Profit Margin----9.3540%-3.4140%-3.4930%-93.0660%
Operating Margin----9.3860%-3.2600%-3.5120%-91.3450%
Operating Ratio---10.163-100%4.518-100%4.523-100%179.522-100%
Pb Ratio15.161+17%12.62012.816-2%10.697+18%15.229-17%12.151+4%
Pe Ratio-4.246-20%-3.535-5.633+59%-8.174+131%-65.090+1741%-33.662+852%
Price Per Share23.270+17%19.37026.140-26%32.123-40%44.017-56%26.737-28%
Price To Free Cash Flow Ratio-4.484-20%-3.732-5.525+48%-12.525+236%-26.451+609%-15.823+324%
Price To Total Gains Ratio-19.567-20%-16.288-14.866-9%-6.321-61%-499.343+2966%-274.505+1585%
Quick Ratio--12.20610.153+20%10.240+19%8.561+43%7.661+59%
Return On Assets---0.150-0.172+15%-0.066-56%-0.078-48%-0.089-41%
Return On Equity---0.920-0.631-31%-0.172-81%-0.238-74%-0.178-81%
Total Gains Per Share---1.189-0.193-84%0.364-427%-0.021-98%0.005-23768%
Usd Book Value--191063000.000299789000.000-36%382656250.000-50%391396672.500-51%256566630.600-26%
Usd Book Value Change Per Share---1.189-0.193-84%0.364-427%-0.021-98%0.005-23768%
Usd Book Value Per Share--1.5352.409-36%3.075-50%3.145-51%2.062-26%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Enterprise Value--2143376356.0003116717704.000-31%4003277415.000-46%5555647701.350-61%3401474597.350-37%
Usd Eps---1.370-1.204-12%-0.412-70%-0.483-65%-0.281-80%
Usd Free Cash Flow---161505000.000-151080000.000-6%-82656750.000-49%-54177064.100-66%-28474384.325-82%
Usd Free Cash Flow Per Share---1.297-1.214-6%-0.664-49%-0.435-66%-0.229-82%
Usd Free Cash Flow To Equity Per Share--1.8280.535+242%-0.156+109%0.150+1115%0.103+1676%
Usd Market Cap2895579180.000+17%2411154356.0003252921704.000-26%3997131165.000-40%5477254766.800-56%3327060215.150-28%
Usd Price Per Share23.270+17%19.37026.140-26%32.123-40%44.017-56%26.737-28%
Usd Profit---170536000.000-149873250.000-12%-51440250.000-70%-60314311.300-65%-35020090.350-79%
Usd Revenue---887750.000-100%60183750.000-100%35689853.250-100%23267075.150-100%
Usd Total Gains Per Share---1.189-0.193-84%0.364-427%-0.021-98%0.005-23768%
 EOD+5 -3MRQTTM+9 -26YOY+8 -275Y+9 -2610Y+8 -27

3.3 Fundamental Score

Let's check the fundamental score of Arrowhead Pharmaceuticals Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.246
Price to Book Ratio (EOD)Between0-115.161
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than112.206
Current Ratio (MRQ)Greater than16.741
Debt to Asset Ratio (MRQ)Less than10.832
Debt to Equity Ratio (MRQ)Less than15.116
Return on Equity (MRQ)Greater than0.15-0.920
Return on Assets (MRQ)Greater than0.05-0.150
Total3/10 (30.0%)

3.4 Technical Score

Let's check the technical score of Arrowhead Pharmaceuticals Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.698
Ma 20Greater thanMa 5021.748
Ma 50Greater thanMa 10020.551
Ma 100Greater thanMa 20022.201
OpenGreater thanClose23.670
Total3/5 (60.0%)

4. In-depth Analysis

4.1 About Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Fundamental data was last updated by Penke on 2024-12-05 12:54:06.

4.2 In-depth Summary

4.2.1. Financial Health Summary

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

4.2.2. Valuation Summary

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is expensive.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.
3rd party ad coffee SUPPORTERis ad-free.

4.3 Financial Health

4.3.1. Profitability

4.3.1 Profitability
4.3.1.1. Net Profit Margin

Measures how much net profit Arrowhead Pharmaceuticals Inc earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Arrowhead Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that $0.00 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Arrowhead Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-935.4%+935.4%
TTM-935.4%YOY-341.4%-594.0%
TTM-935.4%5Y-349.3%-586.1%
5Y-349.3%10Y-9,306.6%+8,957.3%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--109.4%+109.4%
TTM-935.4%-221.4%-714.0%
YOY-341.4%-208.7%-132.7%
5Y-349.3%-346.2%-3.1%
10Y-9,306.6%-470.4%-8,836.2%
4.3.1.2. Return on Assets

Shows how efficient Arrowhead Pharmaceuticals Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Arrowhead Pharmaceuticals Inc to the Biotechnology industry mean.
  • -15.0% Return on Assets means that Arrowhead Pharmaceuticals Inc generated $-0.15 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Arrowhead Pharmaceuticals Inc:

  • The MRQ is -15.0%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -17.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-15.0%TTM-17.2%+2.2%
TTM-17.2%YOY-6.6%-10.5%
TTM-17.2%5Y-7.8%-9.3%
5Y-7.8%10Y-8.9%+1.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-15.0%-11.6%-3.4%
TTM-17.2%-12.0%-5.2%
YOY-6.6%-11.2%+4.6%
5Y-7.8%-12.6%+4.8%
10Y-8.9%-14.2%+5.3%
4.3.1.3. Return on Equity

Shows how efficient Arrowhead Pharmaceuticals Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Arrowhead Pharmaceuticals Inc to the Biotechnology industry mean.
  • -92.0% Return on Equity means Arrowhead Pharmaceuticals Inc generated $-0.92 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Arrowhead Pharmaceuticals Inc:

  • The MRQ is -92.0%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -63.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-92.0%TTM-63.1%-28.9%
TTM-63.1%YOY-17.2%-45.9%
TTM-63.1%5Y-23.8%-39.3%
5Y-23.8%10Y-17.8%-6.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-92.0%-14.5%-77.5%
TTM-63.1%-16.0%-47.1%
YOY-17.2%-14.6%-2.6%
5Y-23.8%-18.6%-5.2%
10Y-17.8%-19.3%+1.5%
3rd party ad coffee SUPPORTERis ad-free.

4.3.2. Operating Efficiency of Arrowhead Pharmaceuticals Inc.

4.3.2. Operating Efficiency
4.3.2.1. Operating Margin

Measures how efficient Arrowhead Pharmaceuticals Inc is operating .

  • Measures how much profit Arrowhead Pharmaceuticals Inc makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Arrowhead Pharmaceuticals Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated $0.00  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Arrowhead Pharmaceuticals Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-938.6%+938.6%
TTM-938.6%YOY-326.0%-612.7%
TTM-938.6%5Y-351.2%-587.4%
5Y-351.2%10Y-9,134.5%+8,783.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--203.3%+203.3%
TTM-938.6%-316.3%-622.3%
YOY-326.0%-216.5%-109.5%
5Y-351.2%-378.6%+27.4%
10Y-9,134.5%-480.3%-8,654.2%
4.3.2.2. Operating Ratio

Measures how efficient Arrowhead Pharmaceuticals Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are $0.00 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Arrowhead Pharmaceuticals Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM10.163-10.163
TTM10.163YOY4.518+5.645
TTM10.1635Y4.523+5.640
5Y4.52310Y179.522-174.998
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-2.284-2.284
TTM10.1633.198+6.965
YOY4.5183.263+1.255
5Y4.5234.651-0.128
10Y179.5226.419+173.103
3rd party ad coffee SUPPORTERis ad-free.

4.4.3. Liquidity of Arrowhead Pharmaceuticals Inc.

4.4.3. Liquidity
4.4.3.1. Current Ratio

Measures if Arrowhead Pharmaceuticals Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 6.74 means the company has $6.74 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Arrowhead Pharmaceuticals Inc:

  • The MRQ is 6.741. The company is very able to pay all its short-term debts. +2
  • The TTM is 5.860. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ6.741TTM5.860+0.881
TTM5.860YOY6.210-0.350
TTM5.8605Y5.600+0.259
5Y5.60010Y5.543+0.057
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.7413.601+3.140
TTM5.8603.872+1.988
YOY6.2104.655+1.555
5Y5.6005.973-0.373
10Y5.5436.258-0.715
4.4.3.2. Quick Ratio

Measures if Arrowhead Pharmaceuticals Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Arrowhead Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Quick Ratio of 12.21 means the company can pay off $12.21 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Arrowhead Pharmaceuticals Inc:

  • The MRQ is 12.206. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 10.153. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ12.206TTM10.153+2.053
TTM10.153YOY10.240-0.087
TTM10.1535Y8.561+1.592
5Y8.56110Y7.661+0.900
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ12.2063.093+9.113
TTM10.1533.416+6.737
YOY10.2404.393+5.847
5Y8.5615.954+2.607
10Y7.6616.436+1.225
3rd party ad coffee SUPPORTERis ad-free.

4.5.4. Solvency of Arrowhead Pharmaceuticals Inc.

4.5.4. Solvency
4.5.4.1. Debt to Asset Ratio

Measures how much % of Arrowhead Pharmaceuticals Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Arrowhead Pharmaceuticals Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.83 means that Arrowhead Pharmaceuticals Inc assets are financed with 83.2% credit (debt) and the remaining percentage (100% - 83.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Arrowhead Pharmaceuticals Inc:

  • The MRQ is 0.832. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.663. The company is able to pay all its debts by selling its assets. +1
Trends
Current periodCompared to+/- 
MRQ0.832TTM0.663+0.169
TTM0.663YOY0.545+0.119
TTM0.6635Y0.433+0.231
5Y0.43310Y0.330+0.102
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.8320.345+0.487
TTM0.6630.346+0.317
YOY0.5450.311+0.234
5Y0.4330.365+0.068
10Y0.3300.382-0.052
4.5.4.2. Debt to Equity Ratio

Measures if Arrowhead Pharmaceuticals Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Arrowhead Pharmaceuticals Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 511.6% means that company has $5.12 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Arrowhead Pharmaceuticals Inc:

  • The MRQ is 5.116. The company is unable to pay all its debts with equity. -1
  • The TTM is 2.634. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ5.116TTM2.634+2.482
TTM2.634YOY1.291+1.343
TTM2.6345Y1.295+1.339
5Y1.29510Y0.809+0.486
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ5.1160.393+4.723
TTM2.6340.431+2.203
YOY1.2910.384+0.907
5Y1.2950.452+0.843
10Y0.8090.497+0.312
3rd party ad coffee SUPPORTERis ad-free.

4.6. Market Valuation

4.6.1. Earnings Per Share
4.6.2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Arrowhead Pharmaceuticals Inc generates.

  • Above 15 is considered overpriced but always compare Arrowhead Pharmaceuticals Inc to the Biotechnology industry mean.
  • A PE ratio of -3.53 means the investor is paying $-3.53 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Arrowhead Pharmaceuticals Inc:

  • The EOD is -4.246. Based on the earnings, the company is expensive. -2
  • The MRQ is -3.535. Based on the earnings, the company is expensive. -2
  • The TTM is -5.633. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.246MRQ-3.535-0.712
MRQ-3.535TTM-5.633+2.099
TTM-5.633YOY-8.174+2.541
TTM-5.6335Y-65.090+59.456
5Y-65.09010Y-33.662-31.427
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.246-2.259-1.987
MRQ-3.535-2.480-1.055
TTM-5.633-3.148-2.485
YOY-8.174-3.244-4.930
5Y-65.090-5.991-59.099
10Y-33.662-6.692-26.970
4.6.2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Arrowhead Pharmaceuticals Inc:

  • The EOD is -4.484. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -3.732. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -5.525. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.484MRQ-3.732-0.751
MRQ-3.732TTM-5.525+1.792
TTM-5.525YOY-12.525+7.000
TTM-5.5255Y-26.451+20.926
5Y-26.45110Y-15.823-10.627
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.484-2.995-1.489
MRQ-3.732-3.289-0.443
TTM-5.525-3.668-1.857
YOY-12.525-4.472-8.053
5Y-26.451-8.001-18.450
10Y-15.823-9.190-6.633
3rd party ad coffee SUPPORTERis ad-free.
4.6.2. Book Value per Share
4.6.2.1. Price to Book Ratio

Measures if the stock price of Arrowhead Pharmaceuticals Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 12.62 means the investor is paying $12.62 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Arrowhead Pharmaceuticals Inc:

  • The EOD is 15.161. Based on the equity, the company is expensive. -2
  • The MRQ is 12.620. Based on the equity, the company is expensive. -2
  • The TTM is 12.816. Based on the equity, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD15.161MRQ12.620+2.541
MRQ12.620TTM12.816-0.196
TTM12.816YOY10.697+2.119
TTM12.8165Y15.229-2.414
5Y15.22910Y12.151+3.078
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD15.1612.001+13.160
MRQ12.6202.054+10.566
TTM12.8162.385+10.431
YOY10.6972.431+8.266
5Y15.2293.690+11.539
10Y12.1514.307+7.844
4.6.2. Total Gains per Share

4.7 Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Arrowhead Pharmaceuticals Inc.

4.8.1. Institutions holding Arrowhead Pharmaceuticals Inc

Institutions are holding 79.707% of the shares of Arrowhead Pharmaceuticals Inc.

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-06-30BlackRock Inc12.60360.0092156832063365692.1931
2024-09-30Vanguard Group Inc9.82770.004212229055149540.1224
2024-09-30venBio Select Advisor LLC7.14342.5106888888800
2024-09-30State Street Corp5.10660.00563543315165698.8488
2024-09-30FMR Inc4.87610.00726067569-744664-10.9313
2024-09-30Slate Path Capital LP3.92581.4572488500074600018.0237
2024-09-30T. Rowe Price Investment Management,Inc.2.87270.04183574573101374039.5863
2024-09-30Geode Capital Management, LLC2.38210.00472964119261710.8908
2024-09-30UBS Asset Mgmt Americas Inc1.73120.01072154250-135904-5.9343
2024-09-30JPMorgan Chase & Co1.72650.00322148405-167300-7.2246
2024-09-30Morgan Stanley - Brokerage Accounts1.29050.00231605766-2024790-55.7708
2024-06-30NORGES BANK1.2740.0062158532026339319.9249
2024-09-30Northern Trust Corp1.07110.00421332765100470.7596
2024-09-30Goldman Sachs Group Inc1.02290.004127290194590.7487
2024-09-30Citadel Advisors Llc0.94630.0044117757722913324.1588
2024-09-30Charles Schwab Investment Management Inc0.80920.00371006935125741.2645
2024-09-30Bank of New York Mellon Corp0.69630.0031866399-218670-20.1526
2024-09-30Woodline Partners LP0.69580.1412865794442765.3895
2024-09-30Western Financial Corp/CA0.65929.015382023900
2024-09-30Aquilo Capital Management, LLC0.639511.689795813-112661-12.4011
Total 61.300524.927276278905-181104-0.2%

4.9.2. Funds holding Arrowhead Pharmaceuticals Inc

DateNameTotal SharesTotal AssetsCurrent SharesChange%
2024-11-27iShares Core S&P Mid-Cap ETF3.2080.1031399179678470.197
2024-10-31Vanguard Total Stock Mkt Idx Inv2.95480.00413676751-26714-0.7213
2024-11-27iShares Russell 2000 ETF2.66580.10753317181-6930-0.2085
2024-10-31Vanguard Small Cap Index2.37770.0374295867058000.1964
2024-11-27SPDR® S&P Biotech ETF1.56790.68741950954-59220-2.946
2024-10-31Vanguard Institutional Extnd Mkt Idx Tr1.5110.03331880144-7125-0.3775
2024-10-31Vanguard Small Cap Growth Index Inv1.30690.08621626292-3971-0.2436
2024-09-30Fidelity Growth Compy Commingled Pl S1.03910.02821293038802726.6189
2024-09-30Fidelity Small Cap Index0.97430.08561212421-9026-0.739
2024-10-31UBS (Lux) Digital Health Equity SB USD0.96442.3048120000000
2024-09-30T. Rowe Price US Small-Cap Core Equity0.89160.2334110949429918436.9222
2024-09-30T. Rowe Price Small-Cap Stock0.89160.23341109494768437.4413
2024-11-27iShares Russell 2000 Growth ETF0.87310.2125108648700
2024-10-31SPDR® S&P MIDCAP 400 ETF Trust0.78580.0825977777-14398-1.4512
2024-09-30Fidelity Growth Company Fund0.74730.0273929869516225.8778
2024-08-31Fidelity Small Cap Growth0.69840.2706869070-2274-0.261
2024-11-27iShares Biotechnology ETF0.6560.30648162878300.1018
2024-09-30JPMorgan Small Cap Growth A0.64860.428480709900
2024-11-27iShares S&P Mid-Cap 400 Growth ETF0.61950.201477085200
2024-10-31State St Russell Sm/Mid Cp® Indx NL Cl C0.58860.0313732435-26100-3.4408
Total 25.97045.504832316111+366640+1.1%

5.3. Insider Transactions

Insiders are holding 4.466% of the shares of Arrowhead Pharmaceuticals Inc.

DateOwnerTypeAmountPricePost Transaction AmountLink
2024-07-02Tracie OliverSELL939425.28
2024-05-02Victoria VakienerSELL179923.31
2024-03-20Hongbo LuBUY100027.5
2024-03-18Hongbo LuBUY100027.49
2024-03-06Kenneth Allen MyszkowskiSELL4000035.19
2024-01-31Christopher Richard AnzaloneSELL5749932.35
2024-01-12James C HamiltonSELL794036.89
2024-01-11Douglas B GivenSELL291138.06
2024-01-05James C HamiltonSELL3214335.18
2024-01-05Kenneth Allen MyszkowskiSELL1610435.27
2024-01-05Patrick O'brienSELL2284135.27
2024-01-03James C HamiltonSELL630032.19
2024-01-03Patrick O'brienSELL874932.28
2024-01-02Christopher Richard AnzaloneSELL995231.01
2023-12-20Christopher Richard AnzaloneSELL1200028.54
3rd party ad coffee SUPPORTERis ad-free.

5. Financial Statements




5.1. Reversals in quarterly reports

I have detected a reversal (positive to negative, negative to positive) in the following values of the quarterly reports.

 2023-09-302023-12-312024-03-312024-06-302024-09-30
Accumulated Other Comprehensive Income  -3,2221,967-1,255160-1,095108-9875,7374,750



5.2. Latest Balance Sheet

Balance Sheet of 2024-09-30. Currency in USD. All numbers in thousands.

Summary
Total Assets1,139,802
Total Liabilities948,739
Total Stockholder Equity185,444
 As reported
Total Liabilities 948,739
Total Stockholder Equity+ 185,444
Total Assets = 1,139,802

Assets

Total Assets1,139,802
Total Current Assets695,471
Long-term Assets444,331
Total Current Assets
Cash And Cash Equivalents 102,685
Short-term Investments 578,276
Other Current Assets 14,510
Total Current Assets  (as reported)695,471
Total Current Assets  (calculated)695,471
+/-0
Long-term Assets
Property Plant Equipment 431,287
Intangible Assets 8,562
Long-term Assets Other 4,482
Long-term Assets  (as reported)444,331
Long-term Assets  (calculated)444,331
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities103,168
Long-term Liabilities845,571
Total Stockholder Equity185,444
Total Current Liabilities
Short-term Debt 6,342
Accounts payable 11,388
Other Current Liabilities 85,438
Total Current Liabilities  (as reported)103,168
Total Current Liabilities  (calculated)103,168
+/-0
Long-term Liabilities
Long term Debt 393,183
Capital Lease Obligations 117,369
Long-term Liabilities  (as reported)845,571
Long-term Liabilities  (calculated)510,552
+/- 335,019
Total Stockholder Equity
Common Stock217
Retained Earnings -1,625,523
Accumulated Other Comprehensive Income 4,750
Other Stockholders Equity 1,806,000
Total Stockholder Equity (as reported)185,444
Total Stockholder Equity (calculated)185,444
+/-0
Other
Capital Stock217
Cash and Short Term Investments 680,961
Common Stock Shares Outstanding 124,479
Liabilities and Stockholders Equity 1,139,802
Net Debt 407,867
Net Invested Capital 578,627
Net Working Capital 592,303
Property Plant and Equipment Gross 489,308
Short Long Term Debt Total 510,552



5.3. Balance Sheets Structured

Currency in USD. All numbers in thousands.

 Trend2024-09-302024-06-302024-03-312023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-312012-12-312012-09-302012-06-302012-03-312011-12-312011-09-302011-06-302011-03-312010-12-312010-09-302010-06-302010-03-312009-12-312009-09-302009-06-302009-03-312008-12-312008-09-302008-06-302008-03-312007-12-312007-09-302007-06-302007-03-312006-12-312006-09-302006-06-302006-03-312005-12-312005-09-302005-06-302005-03-312004-12-312004-09-302004-06-302004-03-312003-12-312003-09-302003-06-302003-03-312002-12-312002-09-302002-06-302002-03-312001-12-312001-09-302001-06-302001-03-312000-12-312000-09-302000-06-302000-03-311999-12-311999-09-301999-06-301999-03-311998-12-311998-09-301998-06-301998-03-31
> Total Assets 
100
100
100
0
100
100
100
100
69
67
65
62
58
58
46
49
50
105
64
64
43
46
1,516
1,516
11,509
12,148
11,916
10,022
14,558
30,707
29,041
25,880
45,085
40,583
34,526
34,394
26,905
36,716
29,853
30,664
24,822
19,126
17,255
15,390
10,168
8,199
7,702
9,129
7,758
14,596
12,355
15,190
15,237
13,290
15,889
23,062
20,081
16,488
16,528
15,231
12,419
41,488
37,330
92,692
202,641
196,623
182,817
162,137
162,378
145,190
132,268
111,381
94,607
85,533
128,177
144,258
126,872
115,082
104,022
88,220
126,999
112,903
111,610
340,947
333,940
336,828
349,845
587,602
561,076
555,728
522,504
499,251
756,795
734,927
710,148
638,539
703,575
751,782
691,939
891,489
891,308
795,856
765,552
626,286
955,150
883,759
1,139,802
1,139,802883,759955,150626,286765,552795,856891,308891,489691,939751,782703,575638,539710,148734,927756,795499,251522,504555,728561,076587,602349,845336,828333,940340,947111,610112,903126,99988,220104,022115,082126,872144,258128,17785,53394,607111,381132,268145,190162,378162,137182,817196,623202,64192,69237,33041,48812,41915,23116,52816,48820,08123,06215,88913,29015,23715,19012,35514,5967,7589,1297,7028,19910,16815,39017,25519,12624,82230,66429,85336,71626,90534,39434,52640,58345,08525,88029,04130,70714,55810,02211,91612,14811,5091,5161,516464364641055049465858626567691001001001000100100100
   > Total Current Assets 
0
0
0
0
0
0
0
16
17
16
16
15
58
58
46
48
48
70
32
32
15
20
1,514
1,514
11,499
10,937
9,497
7,313
9,702
25,665
22,814
19,519
36,113
31,342
28,776
28,807
22,494
32,106
25,305
26,208
20,547
14,541
10,561
9,021
4,178
2,755
2,484
4,148
2,990
10,126
8,132
11,041
8,581
7,049
9,861
9,174
8,818
5,903
6,567
6,064
3,740
34,411
28,844
76,412
161,923
163,423
154,801
132,165
120,147
114,688
102,871
82,284
66,143
49,601
90,503
106,230
89,690
77,902
67,903
53,107
92,660
61,870
78,769
248,951
234,970
244,539
265,247
507,614
314,474
315,233
322,370
323,716
586,757
525,955
384,597
338,278
417,630
432,388
376,396
501,831
574,810
470,165
419,521
237,899
541,650
450,062
695,471
695,471450,062541,650237,899419,521470,165574,810501,831376,396432,388417,630338,278384,597525,955586,757323,716322,370315,233314,474507,614265,247244,539234,970248,95178,76961,87092,66053,10767,90377,90289,690106,23090,50349,60166,14382,284102,871114,688120,147132,165154,801163,423161,92376,41228,84434,4113,7406,0646,5675,9038,8189,1749,8617,0498,58111,0418,13210,1262,9904,1482,4842,7554,1789,02110,56114,54120,54726,20825,30532,10622,49428,80728,77631,34236,11319,51922,81425,6659,7027,3139,49710,93711,4991,5141,5142015323270484846585815161617160000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
1
1
2
0
0
1
0
2
3
57
18
18
0
5
1,355
1,355
10,331
9,839
8,553
6,766
9,311
25,118
22,467
19,105
16,585
16,688
28,020
28,267
21,592
3,421
24,120
25,424
19,522
13,823
10,094
7,637
3,557
1,909
2,020
3,810
2,593
8,983
6,847
5,467
4,790
4,316
7,507
6,773
3,595
2,283
3,377
2,931
3,313
29,026
19,114
59,713
142,848
138,350
132,511
103,991
96,447
87,253
81,214
62,165
50,301
43,617
85,366
102,106
61,719
38,383
24,839
11,531
69,805
27,995
30,133
189,773
161,639
188,332
221,804
461,032
256,651
219,323
143,583
139,921
372,377
325,981
184,434
91,587
86,408
139,439
108,005
202,249
134,959
105,334
110,891
58,215
127,704
69,399
102,685
102,68569,399127,70458,215110,891105,334134,959202,249108,005139,43986,40891,587184,434325,981372,377139,921143,583219,323256,651461,032221,804188,332161,639189,77330,13327,99569,80511,53124,83938,38361,719102,10685,36643,61750,30162,16581,21487,25396,447103,991132,511138,350142,84859,71319,11429,0263,3132,9313,3772,2833,5956,7737,5074,3164,7905,4676,8478,9832,5933,8102,0201,9093,5577,63710,09413,82319,52225,42424,1203,42121,59228,26728,02016,68816,58519,10522,46725,1189,3116,7668,5539,83910,3311,3551,3555018185732010021100000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
437
808
711
488
289
151
66
77
77
18,709
13,945
0
0
0
27,373
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,253
1,178
635
72
79
109
107
56
0
4,058
9,030
15,913
17,798
23,834
21,653
23,532
19,561
23,281
17,540
14,431
11,160
1,031
0
0
24,910
36,755
40,770
39,169
21,737
32,485
46,400
53,980
56,561
48,567
36,900
40,969
50,959
67,709
171,909
165,406
204,941
190,331
183,355
238,547
315,487
277,057
268,391
299,582
346,046
346,369
292,735
162,064
395,410
367,272
578,276
578,276367,272395,410162,064292,735346,369346,046299,582268,391277,057315,487238,547183,355190,331204,941165,406171,90967,70950,95940,96936,90048,56756,56153,98046,40032,48521,73739,16940,77036,75524,910001,03111,16014,43117,54023,28119,56123,53221,65323,83417,79815,9139,0304,05805610710979726351,1782,2530000000000000027,37300013,94518,70977776615128948871180843700000000000000000000000
       Net Receivables 
0
0
0
0
0
0
0
1
2
2
1
2
1
0
1
1
0
0
0
0
0
0
0
0
0
38
52
3
38
91
33
37
42
37
74
37
2
388
276
403
495
157
87
1,009
169
396
147
133
172
736
931
5,373
1,268
1,350
1,608
2,028
4,687
3,079
2,465
2,616
0
268
84
95
0
0
75
127
0
0
75
0
0
75
75
60
581
937
68
150
16
15
327
3,169
13,422
2,044
661
1,345
1,266
21,693
846
9,002
955
671
10,255
150
1,317
239
1,410
39,568
69,434
1,247
0
0
0
0
0
000001,24769,43439,5681,4102391,31715010,2556719559,00284621,6931,2661,3456612,04413,4223,1693271516150689375816075750075001277500958426802,6162,4653,0794,6872,0281,6081,3501,2685,3739317361721331473961691,0098715749540327638823774374237339138352380000000001101212210000000
       Other Current Assets 
0
0
0
0
0
0
0
1
1
0
1
0
45
45
38
38
38
0
1
1
1
1
159
159
361
348
405
256
202
390
237
377
777
672
681
503
900
924
909
381
530
560
381
375
451
450
316
206
225
69
115
18
271
205
111
301
457
432
618
461
426
1,060
615
690
634
539
49
63
327
655
824
1,904
910
1,507
3,771
3,495
1,748
896
1,360
1,605
358
279
640
478
1,590
1,492
2,563
1,534
2,536
2,412
1,782
2,318
1,845
1,696
2,191
2,795
7,796
8,892
20,204
25,188
14,436
7,162
15,895
17,620
18,536
13,391
14,510
14,51013,39118,53617,62015,8957,16214,43625,18820,2048,8927,7962,7952,1911,6961,8452,3181,7822,4122,5361,5342,5631,4921,5904786402793581,6051,3608961,7483,4953,7711,5079101,90482465532763495396346906151,0604264616184324573011112052711811569225206316450451375381560530381909924900503681672777377237390202256405348361159159111103838384545010110000000
   > Long-term Assets 
100
100
100
0
100
100
100
100
53
50
49
47
0
0
0
0
2
35
31
31
28
26
2
2
10
1,212
2,419
2,708
4,856
5,042
6,227
6,361
8,972
9,241
5,750
5,587
4,410
4,611
4,548
4,456
4,275
4,585
6,694
6,369
5,990
5,444
5,219
4,981
4,768
4,470
4,223
4,149
6,655
6,241
6,027
13,888
11,263
10,585
9,960
9,167
8,679
7,077
8,486
16,281
40,718
33,200
28,016
29,972
42,232
30,503
29,397
29,097
28,464
35,932
37,674
38,028
37,182
37,179
36,119
35,114
34,338
51,033
32,841
91,997
98,970
92,290
84,599
79,987
246,602
240,495
200,133
175,535
170,038
208,972
325,551
300,261
285,945
319,394
315,543
389,658
316,498
325,691
346,031
388,387
413,500
433,697
444,331
444,331433,697413,500388,387346,031325,691316,498389,658315,543319,394285,945300,261325,551208,972170,038175,535200,133240,495246,60279,98784,59992,29098,97091,99732,84151,03334,33835,11436,11937,17937,18238,02837,67435,93228,46429,09729,39730,50342,23229,97228,01633,20040,71816,2818,4867,0778,6799,1679,96010,58511,26313,8886,0276,2416,6554,1494,2234,4704,7684,9815,2195,4445,9906,3696,6944,5854,2754,4564,5484,6114,4105,5875,7509,2418,9726,3616,2275,0424,8562,7082,4191,2121022262831313520000474950531001001001000100100100
       Property Plant Equipment 
100
100
100
0
0
0
100
100
53
50
49
47
0
0
0
0
2
35
31
31
28
26
2
2
10
702
882
1,171
1,134
1,236
1,078
1,026
998
1,078
1,271
1,260
1,167
1,429
1,439
1,426
1,420
1,260
1,245
1,094
904
617
527
432
338
256
141
98
32
30
25
6,927
6,745
5,366
4,896
4,427
4,013
3,793
3,513
3,186
3,290
3,674
3,873
4,124
4,127
4,109
4,527
4,666
4,382
12,275
15,387
16,166
15,715
16,135
15,513
14,932
14,582
14,029
13,935
13,921
13,378
17,075
23,215
36,876
39,626
46,912
47,018
49,477
57,770
66,236
66,021
69,178
71,267
140,812
168,588
188,969
226,342
272,036
335,559
378,318
403,878
420,250
431,287
431,287420,250403,878378,318335,559272,036226,342188,969168,588140,81271,26769,17866,02166,23657,77049,47747,01846,91239,62636,87623,21517,07513,37813,92113,93514,02914,58214,93215,51316,13515,71516,16615,38712,2754,3824,6664,5274,1094,1274,1243,8733,6743,2903,1863,5133,7934,0134,4274,8965,3666,7456,927253032981412563384325276179041,0941,2451,2601,4201,4261,4391,4291,1671,2601,2711,0789981,0261,0781,2361,1341,171882702102226283131352000047495053100100000100100100
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
446
399
1,443
2,596
3,704
1,762
1,762,150
4,467
4,507
963
963
3,147
3,043
2,939
2,835
2,731
2,628
2,750
2,642
2,541
2,441
2,362
2,284
2,205
2,126
2,047
1,968
1,852
1,792
1,731
2,750
2,675
4,685
4,785
4,710
4,636
3,254
3,241
3,227
3,213
3,200
1,013
1,000
25,702
25,263
24,824
24,385
23,960
23,535
22,165
-21,718,021
21,315
-20,868,656
20,464
-20,019,293
19,614
-19,169,928
18,764
-18,320,564
17,914
17,489
17,064
-16,621,835
16,213
-15,772,470
15,363
14,938
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000014,93815,363-15,772,47016,213-16,621,83517,06417,48917,914-18,320,56418,764-19,169,92819,614-20,019,29320,464-20,868,65621,315-21,718,02122,16523,53523,96024,38524,82425,26325,7021,0001,0133,2003,2133,2273,2413,2544,6364,7104,7854,6852,6752,7501,7311,7921,8521,9682,0472,1262,2052,2842,3622,4412,5412,6422,7502,6282,7312,8352,9393,0433,1479639634,5074,4671,762,1501,7623,7042,5961,4433994460000000000000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
34,048
26,285
23,088
17,806
12,361
1,085
0
0
0
0
0
0
0
0
0
0
0
17,673
0
59,595
67,536
57,555
44,176
26,329
190,618
177,530
137,487
110,855
97,490
128,376
245,595
217,572
201,590
165,920
105,872
115,774
78,834
42,758
0
0
0
0
0
0000042,75878,834115,774105,872165,920201,590217,572245,595128,37697,490110,855137,487177,530190,61826,32944,17657,55567,53659,595017,673000000000001,08512,36117,80623,08826,28534,0480000000000000000000000000000000000000000000000000000000000000000
       Intangible Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
446
1,461
1,443
3,622
3,704
5,038
5,171
3,323
3,491
3,354
3,250
3,147
3,043
2,939
2,835
2,731
2,628
2,750
2,642
2,541
2,441
2,362
2,284
2,205
2,126
2,047
1,968
1,852
1,792
1,731
2,750
2,675
4,685
4,785
4,710
4,636
3,254
3,241
3,227
3,213
3,200
1,013
1,000
25,702
25,263
24,824
24,385
23,960
23,535
22,165
21,739,761
21,315
20,889,546
20,464
20,039,332
19,614
19,189,117
18,764
18,338,903
17,914
17,489
17,064
16,638,473
16,213
15,788,258
15,363
14,938
14,513
14,088
13,663
13,238
12,813
12,387
11,962
11,537
11,112
10,687
10,262
9,837
9,412
8,987
8,562
8,5628,9879,4129,83710,26210,68711,11211,53711,96212,38712,81313,23813,66314,08814,51314,93815,36315,788,25816,21316,638,47317,06417,48917,91418,338,90318,76419,189,11719,61420,039,33220,46420,889,54621,31521,739,76122,16523,53523,96024,38524,82425,26325,7021,0001,0133,2003,2133,2273,2413,2544,6364,7104,7854,6852,6752,7501,7311,7921,8521,9682,0472,1262,2052,2842,3622,4412,5412,6422,7502,6282,7312,8352,9393,0433,1473,2503,3543,4913,3235,1715,0383,7043,6221,4431,4614460000000000000000000000000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
509
1,537
1,538
3,722
3,806
5,149
5,335
7,974
8,163
4,479
4,327
3,244
3,181
3,109
3,030
2,855
3,325
5,449
5,275
5,086
4,827
4,691
4,549
4,430
4,214
4,082
4,051
6,624
6,211
6,003
6,961
4,518
5,219
5,065
4,740
4,666
3,284
4,972
13,094
37,428
29,526
24,143
25,848
38,104
26,394
24,870
24,431
24,082
23,657
22,287
21,862
21,467
21,045
20,606
20,181
142
142
142
142
142
171
144
144
144
265
68,870
40,855
265
272
96,764
273
275
169,366
209,671
210
210
210
210
0
0
0
0
0000210210210210209,671169,36627527396,76427226540,85568,87026514414414417114214214214214220,18120,60621,04521,46721,86222,28723,65724,08224,43124,87026,39438,10425,84824,14329,52637,42813,0944,9723,2844,6664,7405,0655,2194,5186,9616,0036,2116,6244,0514,0824,2144,4304,5494,6914,8275,0865,2755,4493,3252,8553,0303,1093,1813,2444,3274,4798,1637,9745,3355,1493,8063,7221,5381,5375090000000000000000000000000
> Total Liabilities 
2,700
2,700
2,900
0
2,700
1,000
1,100
1,100
1,176
1,231
1,194
1,221
1,269
1,302
1,351
1,416
1,428
1,571
1,614
1,614
1,744
1,800
96
96
38
373
690
352
579
993
1,024
1,457
2,589
1,729
2,920
1,015
1,146
2,940
3,396
2,783
2,794
3,055
4,953
10,390
9,762
4,485
2,844
2,580
2,280
5,140
4,276
7,902
3,015
2,721
3,324
7,313
8,514
8,039
7,719
7,627
8,659
8,183
11,595
11,782
13,104
10,815
16,832
16,427
18,182
14,446
22,646
19,013
20,681
26,108
33,152
47,050
33,535
25,539
23,155
18,021
13,284
11,144
16,369
169,447
133,300
111,158
105,809
88,073
67,512
63,143
60,725
44,779
311,246
298,037
301,326
265,979
251,309
277,605
585,979
495,117
426,202
413,871
478,390
452,572
459,745
544,785
948,739
948,739544,785459,745452,572478,390413,871426,202495,117585,979277,605251,309265,979301,326298,037311,24644,77960,72563,14367,51288,073105,809111,158133,300169,44716,36911,14413,28418,02123,15525,53933,53547,05033,15226,10820,68119,01322,64614,44618,18216,42716,83210,81513,10411,78211,5958,1838,6597,6277,7198,0398,5147,3133,3242,7213,0157,9024,2765,1402,2802,5802,8444,4859,76210,3904,9533,0552,7942,7833,3962,9401,1461,0152,9201,7292,5891,4571,0249935793526903733896961,8001,7441,6141,6141,5711,4281,4161,3511,3021,2691,2211,1941,2311,1761,1001,1001,0002,70002,9002,7002,700
   > Total Current Liabilities 
2,700
2,600
2,800
0
2,600
1,000
1,000
1,000
1,137
1,190
1,155
1,184
1,233
1,267
1,318
1,384
1,397
1,542
1,587
1,587
1,716
1,773
96
96
38
373
690
352
579
993
1,024
1,457
2,589
1,729
2,920
1,015
1,146
2,940
2,896
2,283
2,294
2,555
3,726
4,860
4,449
3,410
2,344
2,580
2,280
5,140
4,276
7,902
2,495
2,160
2,582
5,060
6,376
5,815
5,328
6,078
7,164
6,678
8,725
9,018
10,483
8,250
11,847
11,498
13,210
9,532
15,901
12,328
14,058
14,840
25,644
36,998
27,552
20,320
18,701
13,716
9,124
7,127
12,365
134,612
101,812
87,087
97,071
73,695
53,333
42,783
40,681
25,094
167,188
195,434
146,536
137,032
138,857
128,212
74,099
66,281
87,151
70,227
105,456
63,723
65,175
96,714
103,168
103,16896,71465,17563,723105,45670,22787,15166,28174,099128,212138,857137,032146,536195,434167,18825,09440,68142,78353,33373,69597,07187,087101,812134,61212,3657,1279,12413,71618,70120,32027,55236,99825,64414,84014,05812,32815,9019,53213,21011,49811,8478,25010,4839,0188,7256,6787,1646,0785,3285,8156,3765,0602,5822,1602,4957,9024,2765,1402,2802,5802,3443,4104,4494,8603,7262,5552,2942,2832,8962,9401,1461,0152,9201,7292,5891,4571,0249935793526903733896961,7731,7161,5871,5871,5421,3971,3841,3181,2671,2331,1841,1551,1901,1371,0001,0001,0002,60002,8002,6002,700
       Short-term Debt 
0
0
0
0
0
0
0
525
525
523
524
525
526
526
526
526
506
606
606
606
603
602
0
0
0
0
0
0
0
0
0
632
633
0
0
0
0
0
1,041
892
0
0
810
827
843
860
727
1,014
796
575
500
500
0
958
945
210
212
213
215
1,152
1,098
1,145
1,193
1,271
1,262
263
264
214
216
217
218
218
219
361
194
198
201
205
209
212
216
220
224
224
0
0
11,635
461
688
1,012
1,095
1,183
1,272
1,290
2,250
2,826
2,910
2,883
2,776
2,664
2,711
2,823
21,126
6,842
5,285
12,106
6,342
6,34212,1065,2856,84221,1262,8232,7112,6642,7762,8832,9102,8262,2501,2901,2721,1831,0951,01268846111,635002242242202162122092052011981943612192182182172162142642631,2621,2711,1931,1451,0981,15221521321221094595805005005757961,014727860843827810008921,041000006336320000000006026036066066065065265265265265255245235255250000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
50
0
0
0
758
0
0
1,430
194
317
347
2,583
209
212
216
220
224
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000002242202162122092,5833473171941,4300075800050000000000000000000000000000000000000000000000000000000000000000000
       Accounts payable 
1,100
1,100
1,400
0
1,000
200
200
200
209
229
161
156
168
167
180
208
243
247
259
259
299
317
93
93
32
297
541
284
445
343
472
491
1,715
209
847
392
490
1,454
1,349
881
1,161
1,084
1,342
1,911
2,002
1,399
1,013
892
884
1,033
682
2,424
236
501
577
714
801
994
878
810
872
1,062
1,200
589
2,512
2,158
2,579
5,995
4,936
4,862
5,032
5,289
7,542
5,945
12,233
3,698
2,598
3,233
4,077
5,707
1,810
2,166
2,806
3,937
4,062
4,630
7,650
12,202
13,418
4,074
6,829
4,827
5,299
10,037
9,457
4,068
10,603
5,894
2,868
796
9,556
7,874
35,866
4,460
8,521
26,550
11,388
11,38826,5508,5214,46035,8667,8749,5567962,8685,89410,6034,0689,45710,0375,2994,8276,8294,07413,41812,2027,6504,6304,0623,9372,8062,1661,8105,7074,0773,2332,5983,69812,2335,9457,5425,2895,0324,8624,9365,9952,5792,1582,5125891,2001,0628728108789948017145775012362,4246821,0338848921,0131,3992,0021,9111,3421,0841,1618811,3491,4544903928472091,7154914723434452845412973293933172992592592472432081801671681561612292092002002001,00001,4001,1001,100
       Other Current Liabilities 
1,600
1,500
1,400
0
1,600
800
800
800
403
438
471
503
539
574
0
650
648
689
722
722
814
853
3
3
7
76
149
68
135
506
446
265
211
1,519
2,074
624
656
1,108
408
473
1,133
1,472
479
485
311
283
184
674
599
2,618
2,409
1,943
2,259
1,658
2,005
4,035
5,293
4,536
4,198
4,007
5,128
4,399
6,229
7,048
6,643
5,757
8,900
5,179
7,993
4,382
10,548
6,711
6,231
8,508
10,647
7,518
3,583
3,598
9,146
5,922
5,532
3,798
9,334
5,750
6,860
6,775
17
6,998
6,053
11,423
13,467
12,340
15,738
33,173
23,774
21,486
27,475
35,147
-5,644
-3,460
45,045
42,625
47,598
52,421
51,369
58,058
85,438
85,43858,05851,36952,42147,59842,62545,045-3,460-5,64435,14727,47521,48623,77433,17315,73812,34013,46711,4236,0536,998176,7756,8605,7509,3343,7985,5325,9229,1463,5983,5837,51810,6478,5086,2316,71110,5484,3827,9935,1798,9005,7576,6437,0486,2294,3995,1284,0074,1984,5365,2934,0352,0051,6582,2591,9432,4092,6185996741842833114854791,4721,1334734081,1086566242,0741,519211265446506135681497673385381472272268964865005745395034714384038008008001,60001,4001,5001,600
   > Long-term Liabilities 
0
100
100
0
100
0
100
100
39
41
39
38
36
35
33
32
31
29
28
28
28
28
0
0
0
928
1,778
0
1,536
0
1,889
1,092,753
0
1,229,462
934,438
3,216,137
0
600,038
500
500
500
500
1,227
5,530
5,313
1,075
500
500
0
0
0
0
520
561
742
2,253
2,139
2,224
2,391
1,549
1,495
1,505
2,870
2,764
2,621
2,565
4,984
4,929
4,972
4,913
6,746
6,685
6,623
11,268
7,508
10,052
5,984
5,220
4,454
4,305
4,160
4,017
4,004
34,836
31,488
24,071
8,739
14,378
14,179
20,360
20,043
19,685
144,058
102,603
154,790
128,947
112,452
149,393
511,880
428,836
339,051
343,644
372,934
388,849
394,570
448,071
845,571
845,571448,071394,570388,849372,934343,644339,051428,836511,880149,393112,452128,947154,790102,603144,05819,68520,04320,36014,17914,3788,73924,07131,48834,8364,0044,0174,1604,3054,4545,2205,98410,0527,50811,2686,6236,6856,7464,9134,9724,9294,9842,5652,6212,7642,8701,5051,4951,5492,3912,2242,1392,25374256152000005005001,0755,3135,5301,227500500500500600,03803,216,137934,4381,229,46201,092,7531,88901,53601,7789280002828282829313233353638394139100100010001001000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
561
607
2,147
2,139
2,130
2,122
1,278
1,223
1,167
1,111
1,006
866
812
758
705
650
596
541
486
431
2,962
2,533
2,483
2,431
2,379
2,325
2,271
2,215
2,159
2,101
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000002,1012,1592,2152,2712,3252,3792,4312,4832,5332,9624314865415966507057588128661,0061,1111,1671,2231,2782,1222,1302,1392,14760756100000000000000000000000000000000000000000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
500
500
500
500
500
500
500
0
0
0
0
0
0
0
0
0
136
106
0
93
269
271
272
337
1,759
1,758
1,754
1,753
4,227
4,225
4,322
4,318
6,204
6,199
6,192
8,306
4,976
7,569
3,552
2,841
2,129
2,034
1,945
1,858
1,903
34,836
31,488
24,071
8,739
0
0
0
41,434
0
121,530
79,749
190,271
106,458
89,754
193,317
199,501
293,638
258,981
263,733
0
0
0
0
0
00000263,733258,981293,638199,501193,31789,754106,458190,27179,749121,530041,4340008,73924,07131,48834,8361,9031,8581,9452,0342,1292,8413,5527,5694,9768,3066,1926,1996,2044,3184,3224,2254,2271,7531,7541,7581,75933727227126993010613600000000050050050050050050050000000000000000000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
2,243
4,775
7,369
3,352
2,641
1,929
1,834
1,745
1,658
1,703
1,664
1,755
1,812
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000001,8121,7551,6641,7031,6581,7451,8341,9292,6413,3527,3694,7752,2430000000000000000000000000000000000000000000000000000000000000000000000000
> Total Stockholder Equity
-2,600
-2,600
-2,800
0
-2,600
-900
-1,000
-1,000
-1,106
-1,164
-1,129
-1,159
-1,211
-1,244
-1,304
-1,368
-1,378
-1,466
-1,551
-1,551
-1,701
-1,754
1,420
1,420
11,471
10,847
9,448
8,223
12,443
28,457
26,127
23,331
41,200
37,625
30,671
30,162
24,477
33,176
26,304
23,771
19,064
13,100
12,303
5,000
406
3,714
4,858
6,671
5,878
10,113
9,046
8,049
12,085
10,626
12,791
16,169
12,236
9,365
10,013
8,975
5,313
34,957
27,499
82,732
191,399
186,363
166,540
146,265
144,752
131,300
110,177
92,924
74,481
59,980
95,579
97,764
93,892
90,097
81,422
70,754
114,270
102,315
95,796
172,055
201,195
226,225
244,591
500,084
494,119
493,140
461,779
454,472
445,549
436,890
408,822
372,560
452,266
453,927
105,960
377,039
446,772
364,830
271,343
160,407
483,794
330,547
185,444
185,444330,547483,794160,407271,343364,830446,772377,039105,960453,927452,266372,560408,822436,890445,549454,472461,779493,140494,119500,084244,591226,225201,195172,05595,796102,315114,27070,75481,42290,09793,89297,76495,57959,98074,48192,924110,177131,300144,752146,265166,540186,363191,39982,73227,49934,9575,3138,97510,0139,36512,23616,16912,79110,62612,0858,0499,04610,1135,8786,6714,8583,7144065,00012,30313,10019,06423,77126,30433,17624,47730,16230,67137,62541,20023,33126,12728,45712,4438,2239,44810,84711,4711,4201,420-1,754-1,701-1,551-1,551-1,466-1,378-1,368-1,304-1,244-1,211-1,159-1,129-1,164-1,106-1,000-1,000-900-2,6000-2,800-2,600-2,600
   Common Stock
0
0
0
0
0
0
0
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
5
14
14
14
14
15
28
28
28
34
34
34
34
34
39
39
39
39
39
43
43
43
46
56
62
64
71
72
72
72
72
86
105
106
106
108
110
109
124
125
131
144
145
147
147
152
152
152
152
152
153
162
167
167
167
167
167
180
180
181
185
187
188
188
193
194
195
195
195
196
197
197
197
198
198
105,960
106,140
199
199
200
200
217
217
217
217217217200200199199106,140105,96019819819719719719619519519519419318818818718518118018016716716716716716215315215215215215214714714514413112512410911010810610610586727272727164625646434343393939393934343434342828281514141414555555555555555550000000
   Retained Earnings -1,625,523-1,454,987-1,284,194-1,158,894-1,026,030-916,351-813,405-862,080-820,755-735,244-663,198-707,564-644,692-581,318-551,394-524,576-503,844-455,411-441,800-421,965-419,291-430,996-451,332-475,229-487,266-476,505-460,899-446,014-432,815-422,083-416,564-410,521-398,435-376,213-356,792-335,976-316,712-291,969-276,033-247,346-224,771-202,341-190,712-176,769-166,141-152,449-146,370-139,612-134,998-129,684-121,692-116,357-113,872-111,095-109,275-112,181-110,743-108,739-108,368-106,514-104,969-101,345-98,816-93,527-85,496-76,838-69,336-63,641-58,407-50,835-38,357-32,183-28,476-19,697-15,723-12,616-9,217-6,522-3,486-4,129-2,592-1,115-477-95-95-9,816-9,763-9,613-9,613-9,528-9,440-9,430-9,367-9,306-9,273-9,222-9,181-9,216-9,158-9,000-9,000-9,900-9,5000-9,600-9,400-9,400
   Accumulated Other Comprehensive Income 
-100
-100
-100
0
-100
-100
-100
-100
-66
-68
-69
-72
-2
-2
-11
-11
-11
-81
-82
-82
-85
-87
0
0
-1
-528
-194
-334
-263
-690
-728
-3,208
-3,074
-4,971
-1,088
-1,215
-1,345
-1,494
-1,676
-1,857
-2,051
-1,412
-1,596
-1,775
-1,915
-929
-1,025
-1,121
-1,214
-1,296
-1,176
-1,220
-396
-336
-340
-723
-1,072
-1,421
-1,566
-1,941
-2,316
-2,696
-3,081
-3,276
-3,673
-3,933
-4,190
-4,447
-64
-66
-136
-91
60
-31
7
-185
-31
-18
33
24
25
-3
-22
-44
-72
-103
-392
-196
-629
-175
18
198
102
62
-69
-108
-107
-140
-136
-258
-332
-411
-3,222
-1,255
-1,095
-987
4,750
4,750-987-1,095-1,255-3,222-411-332-258-136-140-107-108-696210219818-175-629-196-392-103-72-44-22-3252433-18-31-1857-3160-91-136-66-64-4,447-4,190-3,933-3,673-3,276-3,081-2,696-2,316-1,941-1,566-1,421-1,072-723-340-336-396-1,220-1,176-1,296-1,214-1,121-1,025-929-1,915-1,775-1,596-1,412-2,051-1,857-1,676-1,494-1,345-1,215-1,088-4,971-3,074-3,208-728-690-263-334-194-528-100-87-85-82-82-81-11-11-11-2-2-72-69-68-66-100-100-100-1000-100-100-100
   Capital Surplus 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
121,649
127,476
136,319
136,488
139,943
145,918
149,976
151,573
187,282
193,515
259,369
381,967
388,558
391,165
393,464
420,697
423,183
426,873
428,839
431,061
436,071
493,845
508,303
510,319
512,032
514,037
516,578
574,964
578,642
582,903
647,143
652,412
657,137
664,086
922,051
936,354
948,532
965,410
978,655
996,645
1,017,949
1,053,386
1,080,035
1,115,373
1,189,113
1,219,213
1,239,178
1,260,310
1,281,393
0
0
0
0
0
000001,281,3931,260,3101,239,1781,219,2131,189,1131,115,3731,080,0351,053,3861,017,949996,645978,655965,410948,532936,354922,051664,086657,137652,412647,143582,903578,642574,964516,578514,037512,032510,319508,303493,845436,071431,061428,839426,873423,183420,697393,464391,165388,558381,967259,369193,515187,282151,573149,976145,918139,943136,488136,319127,476121,64900000000000000000000000000000000000000000000000000000
   Treasury Stock0000000000000000000000000000000000-73,926-92,368-109,622-130,744-144,196-145,710-165,985-185,808-189,538-80,910-25,735-33,306-3,761-7,604-8,8090000000000000000000000000000000000000000000000000000000000
   Other Stockholders Equity 
6,900
6,900
6,900
0
7,000
9,100
8,100
8,100
8,110
8,112
8,114
8,126
8,057
8,057
8,066
8,066
8,066
8,136
8,139
8,137
8,140
8,142
1,510
1,510
11,935
12,477
12,221
12,672
16,176
35,641
36,045
39,127
59,962
62,259
60,201
63,526
64,145
85,466
86,349
89,230
90,412
91,312
99,352
100,259
-1,898,906
105,942
110,796
114,244
115,396
120,077
120,893
121,378
121,685
121,985
126,917
133,144
134,895
140,364
146,468
150,417
153,889
189,978
196,596
262,645
385,640
392,492
395,355
397,912
420,697
423,183
426,873
428,839
431,061
436,071
493,845
508,303
510,319
512,032
514,037
516,578
574,964
578,642
582,903
647,143
652,412
657,137
664,086
922,051
936,354
948,532
965,410
978,655
996,645
1,017,949
1,053,386
1,080,035
1,115,373
1,189,113
820,891
1,133,237
1,260,310
1,281,393
1,300,395
1,320,356
1,768,866
1,786,304
1,806,000
1,806,0001,786,3041,768,8661,320,3561,300,3951,281,3931,260,3101,133,237820,8911,189,1131,115,3731,080,0351,053,3861,017,949996,645978,655965,410948,532936,354922,051664,086657,137652,412647,143582,903578,642574,964516,578514,037512,032510,319508,303493,845436,071431,061428,839426,873423,183420,697397,912395,355392,492385,640262,645196,596189,978153,889150,417146,468140,364134,895133,144126,917121,985121,685121,378120,893120,077115,396114,244110,796105,942-1,898,906100,25999,35291,31290,41289,23086,34985,46664,14563,52660,20162,25959,96239,12736,04535,64116,17612,67212,22112,47711,9351,5101,5108,1428,1408,1378,1398,1368,0668,0668,0668,0578,0578,1268,1148,1128,1108,1008,1009,1007,00006,9006,9006,900



5.4. Balance Sheets

Currency in USD. All numbers in thousands.